{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:10:45Z","timestamp":1793376645287,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.breast.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T16:27:43Z","timestamp":1654187263000},"page":"143-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ovarian reserve in premenopausal women with breast cancer"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-9003","authenticated-orcid":false,"given":"Xiangyun","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2022.05.009_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"21","key":"10.1016\/j.breast.2022.05.009_bib2","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.3390\/ijms20215342","article-title":"The impact of chemotherapy on the ovaries: molecular aspects and the prevention of ovarian damage","volume":"20","author":"Sonigo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2022.05.009_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ctrv.2018.11.006","article-title":"Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application","volume":"72","author":"Lambertini","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.breast.2022.05.009_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE Guideline: management of women with premature ovarian insufficiency","volume":"31","author":"Webber","year":"2016","journal-title":"Hum Reprod"},{"issue":"12","key":"10.1016\/j.breast.2022.05.009_bib5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.05.009_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.breast.2022.05.009_bib7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical Practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2022.05.009_bib8","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA A Cancer J Clin"},{"issue":"19","key":"10.1016\/j.breast.2022.05.009_bib9","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.05.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.008","article-title":"Anti-m\u00fcllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy","volume":"74","author":"Fr\u00e9our","year":"2017","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.breast.2022.05.009_bib11","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with Triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.breast.2022.05.009_bib12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2022.05.009_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2022.05.009_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.fertnstert.2015.09.033","article-title":"Levels of antim\u00fcllerian hormone in serum during the normal menstrual cycle","volume":"105","author":"Lambert-Messerlian","year":"2016","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.breast.2022.05.009_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrendo.2011.224","article-title":"Anti-M\u00fcllerian hormone: an ovarian reserve marker in primary ovarian insufficiency","volume":"8","author":"Visser","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.breast.2022.05.009_bib16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1530\/EC-18-0180","article-title":"Post-chemotherapy serum anti-M\u00fcllerian hormone level predicts ovarian function recovery","volume":"7","author":"Kim","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.breast.2022.05.009_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.fertnstert.2015.11.043","article-title":"Prevention of chemotherapy-induced ovarian damage","volume":"105","author":"Roness","year":"2016","journal-title":"Fertil Steril"},{"issue":"9","key":"10.1016\/j.breast.2022.05.009_bib18","doi-asserted-by":"crossref","first-page":"E1688","DOI":"10.1073\/pnas.1620729114","article-title":"AMH\/MIS as a contraceptive that protects the ovarian reserve during chemotherapy","volume":"114","author":"Kano","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.breast.2022.05.009_bib19","first-page":"246","article-title":"[Summary and expectation of the role of GnRHa in the treatment of breast cancer]","volume":"41","author":"Li","year":"2019","journal-title":"Zhonghua Zhongliu Zazhi"},{"key":"10.1016\/j.breast.2022.05.009_bib20","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.2147\/CMAR.S269249","article-title":"Can anti-m\u00fcllerian hormone Be a reliable biomarker for assessing ovarian function in women postchemotherapy?","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.breast.2022.05.009_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41523-021-00340-7","article-title":"GnRHa protects the ovarian reserve by reducing endoplasmic reticulum stress during cyclophosphamide-based chemotherapy","volume":"7","author":"Li","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2022.05.009_bib22","article-title":"Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial","author":"Zong","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.breast.2022.05.009_bib23","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10815-015-0595-y","article-title":"Diminished ovarian reserve, premature ovarian failure, poor ovarian responder\u2013a plea for universal definitions","volume":"32","author":"Cohen","year":"2015","journal-title":"J Assist Reprod Genet"},{"issue":"12","key":"10.1016\/j.breast.2022.05.009_bib24","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1093\/humrep\/dez215","article-title":"Serum anti-M\u00fcllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation","volume":"34","author":"Liebenthron","year":"2019","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.breast.2022.05.009_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.rbmo.2018.02.004","article-title":"Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy","volume":"36","author":"Decanter","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.breast.2022.05.009_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2022.05.009_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejogrb.2020.09.016","article-title":"Evolution of serum Anti-M\u00fcllerian Hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level","volume":"254","author":"Loubersac","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.breast.2022.05.009_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fonc.2020.00863","article-title":"Prediction of successful ovarian protection using gonadotropin-releasing hormone agonists during chemotherapy in young estrogen receptor-negative breast cancer patients","volume":"10","author":"Lee","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.breast.2022.05.009_bib29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12885-017-3593-x","article-title":"Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial","volume":"17","author":"Wenners","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.breast.2022.05.009_bib30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10815-018-1128-2","article-title":"Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists","volume":"35","author":"Hickman","year":"2018","journal-title":"J Assist Reprod Genet"},{"issue":"8","key":"10.1016\/j.breast.2022.05.009_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1530\/EC-18-0180","article-title":"Post-chemotherapy serum anti-M\u00fcllerian hormone level predicts ovarian function recovery","volume":"7","author":"Kim","year":"2018","journal-title":"Endocr Connect"},{"issue":"11","key":"10.1016\/j.breast.2022.05.009_bib32","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/ijc.33933","article-title":"Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients","volume":"150","author":"Mailliez","year":"2022","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.breast.2022.05.009_bib33","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.fertnstert.2020.01.033","article-title":"Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency","volume":"113","author":"Oktay","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.breast.2022.05.009_bib34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2019.00575","article-title":"Impact of Taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-m\u00fcllerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy","volume":"9","author":"Lambertini","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.breast.2022.05.009_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/09513590.2021.2002294","article-title":"Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation","volume":"38","author":"Kim","year":"2022","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.breast.2022.05.009_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","article-title":"The utility of anti-M\u00fcllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer","volume":"87","author":"Anderson","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622001011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:46:00Z","timestamp":1760777160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977622001011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":36,"alternative-id":["S0960977622001011"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.05.009","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian reserve in premenopausal women with breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}